Global Ventilator-Associated Pneumonia Market Size, Share, Forecast Report, 2020-2027

The global ventilator-associated pneumonia market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 968.92 million in 2018 and is projected to register a 9.45% CAGR over the forecast period.
Ventilator-associated pneumonia is a type of lung infection that affects patients who are on ventilators. It is caused because of lung diseases, neurological diseases, and trauma.
Factors such as the growing prevalence of ventilator-associated pneumonia and increasing incidences of traumatic brain injury are expected to drive the market growth. According to a report published by the National Center for Biotechnology Information (NCBI) in November 2017, the incidence rate for ventilator-associated pneumonia ranges from 5% to 67%, depending upon the case. Moreover, the increasing research and development expenditure for the development of effective treatment for the disease is further boosting the market growth.
However, factors such as expensive diagnostic tests, high ventilator charges, and inappropriate reimbursement scenarios are expected to hamper the market growth.

Segmentation
The global ventilator-associated pneumonia market has been segmented into diagnosis, end users, and region.
Based on diagnosis, the global ventilator-associated pneumonia market has been segmented into clinical, radiological, microbiological, and others. The microbiological diagnosis segment is further classified into blood & pleural fluid cultures, nonquantitative or semi-quantitative airway sampling, and quantitative cultures of airway specimens.
The global ventilator-associated pneumonia market, by end user, has been categorized into hospitals & clinics, research & academic institutes, ambulatory care centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ventilator-associated pneumonia market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European ventilator-associated pneumonia market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.
The ventilator-associated pneumonia market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The ventilator-associated pneumonia market in Middle East & Africa is segmented into the Middle East and Africa.

Key Players
Adenium Biotech ApS (Denmark), Merck & Co., Inc. (US), AstraZeneca (UK), MedImmune (US), Nabriva Therapeutics AG (Ireland), Thermo Fisher Scientific (US), Bayer AG (Germany), Wockhardt (India), Shionogi Inc. (Japan), Cardeas Pharma (US) are some of the key players operating in the global ventilator-associated pneumonia market.

Global Ventilator-Associated Pneumonia Market, by Diagnosis

• Clinical
• Radiological
• Microbiological
• Blood and Pleural Fluid Cultures
• Nonquantitative or Semi-Quantitative Airway Sampling
• Quantitative Cultures of Airway Specimens
• Others

Global Ventilator-Associated Pneumonia Market, by End User

• Hospitals and Clinics
• Research and Academic Institutes
• Ambulatory Care Centers
• Others